Responses Significantly Correlated to Overall Survival Summary: Three ofatumumab Abstracts Have Been Accepted for Presentation at
the ASH Meeting December 6-9, 2008
COPENHAGEN, November 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that three ofatumumab (HuMax-CD20(R)) abstracts have been accepted for presentation at the 50th American Society of Hematology Annual Meeting and Exposition (ASH) December 6-9, 2008. Updated interim efficacy data from the pivotal study evaluating ofatumumab to treat two groups of chronic lymphocytic leukemia (CLL) patients with an unmet medical need will be presented in an oral session. Headline interim data from the study was announced in July 2008.
In addition, two abstracts on pre-clinical ofatumumab data have been accepted for presentation at poster sessions. All three ofatumumab abstracts are available on the ASH website at http://www.hematology.org.
Oral Presentation December 8 at 11:45AM PST - Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial.
Poster I-682 - Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers.
Poster I-683 - Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX.
Ofatumumab is an investigational, new generation, human monoclonal
antibody that targets a distinct membrane proximal, small loop epitope
(specific binding site) of the CD20 molecule on t
|SOURCE Genmab A/S|
Copyright©2008 PR Newswire.
All rights reserved